All News

Article

Cancer and TNF inhibitors

Richard Conway, MBBChBAO, PhD

Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with cancer risk discussions. An oral presentation by Suarez-Almazor et al provided more supportive data on using TNFi in this population.

Richard Conway Tweet
Antifibrotics in RA-ILD @Juge_P_A Discontinuation in 46% (Mainly GI). Improved FVC trajectory - almost stops decline. Abstr#2479 #ACR23 #ACRbest @RheumNow https://t.co/nZW6TVKefL https://t.co/5BX3PhFhOK
David Liew Tweet
drdavidliew
Real-world tolerability of anti-fibrotics (nintedanib, pirfenidone) in RA-ILD @BrighamWomens: patients do drop out because of AEs, but a decent chunk are okay and do get modest benefit @Juge_P_A @jeffsparks #ACR23 ABST2479 @RheumNow https://t.co/BpM14eizmF
Bella Mehta Tweet
bella_mehta
Merging field moving forward - cardio-rheumatology collaboration imp! Calcium scores in older patients with #RA may be the one take away! Very important to risk predict and mitigate CV events . Ofcourse history taking still remains key! session 14T118 #ACR23 @RheumNow https://t.co/xoldFlA8EW
Mike Putman Tweet
EBRheum
Speaking of real RA drugs for RA-ILD... large multicenter study finds 4 in 5 patients who received ABA had lung stabilization Nice to see observational data; this would be an amazing opportunity for a pragmatic open label RCT @RheumNow #ACR23 Abstr 2165 https://t.co/LTpfjTVAur
Robert B Chao, MD Tweet
Always refreshing to hear from another specialist's point of view Cardiologist @Bweber04 on CVD and rheumatologic diseases Increased risk of death, MI and HF exacerbation in our pt population Increased all cause mortality @RheumNow #ACR23 https://t.co/yOkPOmxU4N
Md Yuzaiful Md Yusof Tweet
#ACR23 Late-Breaking Abstr#L09 In a crowded market, you’ve got to stand out. Phase 2 RCT of LNK01001, a highly selective JAK1-i in China: improvement in ACR 20,50,70 vs PBO at WK12. Those in PBO who didn’t meet ACR20 improved after receiving Tx. Very low infections @RheumNow https://t.co/ZbJFNHOtFT
Eric Dein Tweet
ARTIC REWIND: To taper or not? A#L07 #ACR23 @RheumNow RA pts taper TNFi in stable remission No taper group: 85% flare free in 3 yrs Taper grp: only 25% Lower Boolean 2.0 Remission rates Don't taper off a good thing! https://t.co/KnJrEfVFkV
Janet Pope Tweet
Excellent session: Navigating CV risk for #inflammatory #arthritis - view from #cardiology #ACR23 14T118 @RheumNow @ACRheum https://t.co/WKhh0TonE8
Janet Pope Tweet
Is #cardiology now a specialty like #rheumatology with bDMARDs? Many pathways discussed for CVD in #rheumatoid #arthritis. And biologics for lowering lipids too! #ACR23 ⁦@ACRheum⁩ ⁦@RheumNow⁩ 14T118. More overlap of pts over time! https://t.co/blv5GmHTGe
Mike Putman Tweet
EBRheum
I continue to be underwhelmed by nintedanib, esp in RA-ILD Data from INBUILD-ON, f/u study to the INBUILD basket trial Persistent loss of FVC... wonder how pts would have done had they received an RA-active DMARD? Need H2H vs TNFs & real DMARDs @RheumNow #ACR23 Abstr 2158 https://t.co/56PgC6Uc67
sheila Tweet
Summary of diet effects in RA and SLE patients 👇 Dr. Sarah Patterson also shared nutrition resources for pts and clinicians https://t.co/ae6nLrLXca #ACR23 @Rheumnow @rheumarhyme @GerRheumDoc @doktora_ging https://t.co/8HhCHCTGLh
Eric Dein Tweet
Great summary of the big takeaways yesterday at #ACR23. Always love talking to @KDAO2011 @EBRheum @RheumNow We get into the use of MTX, the safety on TNFs and what is in the purview of rheumatology practice https://t.co/jm0a8ndrsi
Mike Putman Tweet
EBRheum
Excellent pragmatic RCT, TNF withdrawal in RA Almost 2/3 flared by 1 yr; at 3 years up to 3 in 4 Supports my practice of generally continuing TNFs long term Also highlights importance of pt preferences; 1 in 4 may do well if they wish to discontinue @RheumNow #ACR23 #ACRBest https://t.co/G4l0DgBP2Z
TheDaoIndex Tweet
KDAO2011
In case you missed it! Watch our ACR Monday Recap of the meeting with me, @RheumNow @EBRheum and @ericdeinmd. #ACR23 @uptoTate https://t.co/GpMdev0Yk7
Janet Pope Tweet
#irAE Baseline immune suppression does NOT protect against worsening synovitis flares when using check point inhibitors in Pts with established #inflammatory #arthritis #ACRbest #ACR23 @ACRheum @RheumNow abst1075 Data from #CanRIO database https://t.co/lOCf8Tbgta
Janet Pope Tweet
#ACR23 highlights from PlenaryII 🙉#RA #ILD seems that #TNFi is equal to other bDMARDs - was thought to worsen /cause it. 🙉Septra should be given with #rituximab and #steroids in #GCA to prevent #infections not just #PJP #ACR23 @RheumNow @ACRheum #ACRbest
×